Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 13/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19376116 | 0.89 | APLNR (0.48) | KDM4EHTTALDH1A1LMNAMAPT | |
| SCHEMBL19375982 | 0.79 | APLNR (0.51) | APLNR | |
| SCHEMBL19375896 | 0.77 | APLNR (0.58) | APLNR | |
| SCHEMBL19376223 | 0.77 | APLNR (0.65) | APLNR | |
| SCHEMBL19376076 | 0.77 | APLNR (0.65) | APLNR | |
| SCHEMBL19376224 | 0.77 | APLNR (0.65) | APLNR | |
| SCHEMBL19376159 | 0.77 | APLNR (0.52) | APLNR | |
| SCHEMBL19376003 | 0.77 | APLNR (0.52) | APLNR | |
| SCHEMBL19405062 | 0.77 | APLNR (0.49) | KDM4EHTTALDH1A1LMNAMAPT | |
| SCHEMBL19001457 | 0.76 | APLNR (0.41) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433247-B1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-08 | — | — | EP | claimed |
| CN-109195963-B | 6-hydroxy-4-oxo-1, 4-dihydropyrimidine-5-carboxamides as APJ agonists | 百时美施贵宝公司 | 2021-04-23 | — | — | CN | claimed |
| US-10590113-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-17 | — | — | US | claimed |
| US-10106528-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-23 | — | — | US | claimed |
| EP-3433247-B1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-109195963-B | 6-hydroxy-4-oxo-1, 4-dihydropyrimidine-5-carboxamides as APJ agonists | 百时美施贵宝公司 | 2021-04-23 | — | — | CN | disclosed |
| US-10590113-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3433247-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | Bristol-Myers Squibb Company (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-10106528-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-23 | — | — | US | disclosed |
| WO-2017165640-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170275272-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | AP2A1, P2RX5, AP3M1 | KDM4E 916/4885HTT 3857/4885ALDH1A1 448/4885 |
| US-10106528-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | AP2A1, P2RX5, AP3M1 | KDM4E 916/4885HTT 3857/4885ALDH1A1 448/4885 |
| US-20170275272-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | AP2A1, P2RX5, AP3M1 | KDM4E 916/4885HTT 3857/4885ALDH1A1 448/4885 |
| US-10590113-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | AP2A1, P2RX5, AP3M1 | KDM4E 916/4885HTT 3857/4885ALDH1A1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.